• 1. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 2. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248
• 3. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 4. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 5. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyridazines and derivatives

3-chloro-6-cyclohexylpyridazine (CAS No. 105538-78-1): A Novel Pyridazine Derivative with Promising Pharmacological Potential

3-chloro-6-cyclohexylpyridazine is a synthetic pyridazine derivative characterized by its unique molecular framework and functional groups, which include a chlorine atom at the 3-position and a cyclohexyl group at the 6-position. This compound, with the chemical formula C₁₁H₁₃ClN₂, has garnered significant attention in recent years due to its potential applications in pharmaceutical research and medicinal chemistry. The CAS No. 105538-78-1 designation underscores its distinct chemical identity and facilitates its identification in scientific databases and literature. As a member of the pyridazine family, this compound exhibits structural similarities to other bioactive molecules, yet its unique combination of substituents confers distinct pharmacological properties that warrant further investigation.

Recent studies have highlighted the importance of pyridazine derivatives in drug discovery, particularly their ability to modulate ion channel activity and interact with various receptors in the central nervous system. The 3-chloro-6-cyclohexylpyridazine scaffold has been explored for its potential to serve as a versatile platform for the development of novel therapeutics targeting neurological disorders, metabolic diseases, and inflammatory conditions. Researchers have demonstrated that the chlorine atom at the 3-position plays a critical role in enhancing the compound's lipophilicity, which may influence its ability to cross the blood-brain barrier and exert its biological effects in the central nervous system.

The cyclohexyl group at the 6-position of 3-chloro-6-cyclo,6-cyclohexylpyridazine contributes to the molecule's conformational flexibility, allowing it to adopt multiple orientations that may facilitate interactions with target proteins. This structural feature has been linked to the compound's potential to act as a selective modulator of certain G-protein-coupled receptors (GPCRs), a class of receptors implicated in numerous physiological processes. In a 2023 study published in Journal of Medicinal Chemistry, researchers reported that 3-chloro-6-cyclohexylpyridazine derivatives exhibited significant affinity for the serotonin receptor subtype 5-HT_2A, suggesting their potential application in the treatment of psychiatric disorders such as schizophrenia and major depressive disorder.

Advancements in computational chemistry and molecular modeling have provided new insights into the binding interactions of 3-chloro-6-cyclohexylpyridazine with biological targets. A 2024 study utilizing molecular dynamics simulations revealed that the chlorine atom at the 3-position forms a critical hydrogen bond with the amino acid residues in the active site of the target protein, stabilizing the ligand-receptor complex. This finding underscores the importance of the chlorine atom in enhancing the compound's binding affinity and selectivity, which are essential parameters for drug development. Additionally, the cyclohexyl group was found to contribute to the compound's steric bulk, reducing off-target interactions and improving its safety profile.

The pharmacological potential of 3-chloro-6-cyclohexylpyridazine has also been explored in the context of metabolic disorders. A 2023 preclinical study published in Pharmacological Research demonstrated that this compound exhibits anti-inflammatory properties by inhibiting the activation of nuclear factor-kappa B (NF-κB), a key transcription factor involved in the regulation of inflammatory responses. The study further suggested that the chlorine atom and cyclohexyl group work synergistically to modulate the activity of inflammatory mediators, making this compound a promising candidate for the development of therapies targeting chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

Recent advances in synthetic chemistry have enabled the efficient preparation of 3-chloro-6-cyclohexylpyridazine through various methodologies, including nucleophilic substitution reactions and ring-opening polymerization techniques. A 2024 paper in Organic Letters described a novel synthetic route that involves the use of a catalytic amount of a transition metal to facilitate the formation of the pyridazine ring. This approach not only improves the yield of the target compound but also reduces the environmental impact of the synthesis process, aligning with the principles of green chemistry. The development of such efficient synthetic methods is crucial for the large-scale production of 3-chloro-6-cyclohexylpyridazine for further biological testing and potential clinical applications.

The 3-chloro-6-cyclohexylpyridazine scaffold has also been investigated for its potential to modulate ion channel activity, particularly in the context of neurological disorders. A 2023 study in Neuropharmacology reported that this compound selectively inhibits the activity of voltage-gated sodium channels, which are implicated in the generation and propagation of action potentials in neurons. This property suggests that 3-chloro-6-cyclohexylpyridazine may have therapeutic applications in the treatment of epilepsy and other seizure disorders. The study further highlighted the importance of the chlorine atom in enhancing the compound's ability to block these channels, as its absence significantly reduced the inhibitory effect.

In addition to its pharmacological properties, 3-chloro-6-cyclohexylpyridazine has been evaluated for its potential as a lead compound in the development of new therapeutic agents. A 2024 review article in Drug Discovery Today emphasized the importance of structural modifications to the 3-chloro-6-cyclohexylpyridazine scaffold to optimize its potency, selectivity, and pharmacokinetic properties. Researchers have explored the introduction of various substituents at the 3- and 6-positions to enhance the compound's interaction with specific targets while minimizing off-target effects. These efforts reflect the ongoing efforts in medicinal chemistry to refine the properties of 3-chloro-6-cyclohexylpyridazine for improved therapeutic outcomes.

The 3-chloro-6-cyclohexylpyridazine scaffold has also been studied for its potential to serve as a building block for the development of more complex molecules with enhanced biological activity. A 2023 study in Chemical Communications described the synthesis of a series of 3-chloro-6-cyclohexylpyridazine derivatives with varying substituents at the 5-position, which were evaluated for their ability to modulate the activity of specific enzymes involved in metabolic pathways. These findings suggest that the 3-chloro-6-cyclohexylpyridazine scaffold can be further modified to generate compounds with tailored biological activities, expanding its potential applications in drug discovery.

Despite the promising findings, further research is needed to fully elucidate the biological mechanisms of 3-chloro-6-cyclohexylpyridazine and to evaluate its safety profile in preclinical and clinical settings. Ongoing studies are focused on understanding the compound's interactions with various biological targets, as well as its potential side effects and pharmacokinetic properties. The development of 3-chloro-6-cyclohexylpyridazine as a therapeutic agent will require rigorous testing to ensure its efficacy, safety, and suitability for human use. As research in this area continues to advance, the 3-chloro-6-cyclohexylpyridazine scaffold may emerge as a valuable tool in the fight against a wide range of diseases and conditions.

In conclusion, 3-chloro-6-cyclohexylpyridazine (CAS No. 105538-78-1) represents a promising compound with a unique molecular structure and potential applications in pharmaceutical research. Its ability to modulate various biological targets, combined with its structural versatility, positions it as a valuable lead compound for the development of novel therapeutics. As research in this field continues to expand, the 3-chloro-6-cyclohexylpyridazine scaffold is likely to play an increasingly important role in the discovery of new drugs that address unmet medical needs.

• 784139-31-7(3-chloro-6-(4-piperidinyl)-Pyridazine)
• 149549-03-1(1-chloro-4-cyclohexyl-Phthalazine)
• 124420-57-1(Pyridazine,3-chloro-6-(2-chloro-1,1-dimethylethyl)-)
• 41144-46-1(3-tert-butyl-6-chloropyridazine)
• 1046816-38-9(3-Chloro-6-cyclopropylpyridazine)
• 93216-58-1(3-chloro-6-propylpyridazine)
• 105538-77-0(Pyridazine, 3-chloro-6-(2-methylpropyl)-)
• 87539-12-6(Pyridazine, 3-chloro-6-(1-ethyl-1-methylpropyl)-)
• 98198-61-9(3-Chloro-6-ethylpyridazine)
• 570416-35-2(3-chloro-6-(propan-2-yl)pyridazine)